Successful salvage treatment of recurrent endometrial cancer with multiple lung and abdominal metastases

The prognosis of recurrent endometrial carcinoma is generally poor except for isolated vaginal or pelvic relapse without previous radiation. Recurrences associated with infield failure or distant metastasis carry a poor prognosis. We report a case of recurrent endometrial carcinoma treated with cytoreductive surgery, targeted radiation to lung metastasis defined by CT and PET and adjuvant chemo-hormone therapy followed by maintenance progestin therapy with a good outcome. This case implied that chemo-hormone therapy with targeted radiation should be evaluated in recurrent endometrial cancer with positive progesterone receptor for salvage treatment.

Recurrent endometrial cancer; Chemo-hormone therapy; Targeted radiation; Salvage treatment

[1] Aalders J.G., Abeler V., Kolstad P.: “Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients”. Gynecol. Oncol., 1984, 17, 85.

[2] Kao M.S.: “Management of recurrent endometrial carcinoma”. Chang Gung Med. J., 2004, 27, 639.

[3] Dizon D.S.: “Treatment options for advanced endometrial carcinoma”. Gynecol. Oncol., 2010, 117, 373.

[4] Mountzios G., Bamias A., Voulgaris Z., Rodolakis A., Vlahos G., Gourgoulis G. et al.: “Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model”. Gynecol. Oncol., 2008, 108, 130.

[5] Bureau of Health Promotion Department of Health in Taiwan. http://www.bhp.doh.gov.tw/bhpnet, 2009.

[6] Scarabelli C., Campagnutta E., Giorda G., DePiero G., Sopracordevole F., Quaranta M. et al.: “Maximal cytoreductive surgeryas a reasonable therapeutic alternative for recurrent endometrial carcinoma”. Gynecol. Oncol., 1998, 70, 90.

[7] Awtrey C.S., Cadungog M.G., Leitao M.M., Alektiar K.M., Aghajanian C., Hummer A.J. et al.: “Surgical resection of recurrent endometrial carcinoma”. Gynecol. Oncol., 2006, 102, 480.

[8] Bristow R.E., Santillan A., Zahurak M.L., Gardner G.J., Giuntoli R. L., 2nd, Armstrong D.K.: “Salvage cytoreductive surgery for recurrent endometrial cancer”. Gynecol. Oncol., 2006, 103, 281.

[9] Gadducci A., Cosio S., Genazzani A.R.: “Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies”. Crit. Rev. Oncol. Hematol., 2006, 58, 242.

[10] Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H. D., Manetta A. et al.: “Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a doseresponse study by the Gynecologic Oncology Group”. J. Clin. Oncol., 1999, 17, 1736.

[11] Decruze S.B., Green J.A.: “Hormone therapy in advanced and recurrent endometrial cancer: a systematic review”. Int. J. Gynecol. Cancer, 2007, 17, 964.

[12] Pinelli D.M., Fiorica J.V., Roberts W.S., Hoffman M.S., Nicosia S. V., Cavanagh D.: “Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study”. Gynecol. Oncol., 1996, 60, 462.

[13] Markman M.: “Hormonal therapy of endometrial cancer”. Eur. J. Cancer, 2005, 41, 673.

[14] Lai C.H., Yen T.C., Chang T.C.: “Positron emission tomography imaging for gynecologic malignancy”. Curr. Opin. Obstet. Gynecol., 2007, 19, 37.

[15] Chao A., Chang T.C., Ng K.K., Hsueh S., Huang H.J., Chou H.H. et al.: “18F-FDG PET in the management of endometrial cancer”. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, 36.